Literature DB >> 29728405

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Sophie Paczesny1,2, Steven Z Pavletic3, Catherine M Bollard4,1,5.   

Abstract

Immune therapies are fast becoming paradigm-changing treatment options for patients with hematologic cancers. The field has grown exponentially as it expands to nonmalignant blood diseases. This Perspective article introduces the review series describing some of the latest advances in this field and highlighting some of the current obstacles and new opportunities for the future. Specifically, the series provides in-depth discussion on a selection of emerging immunotherapies now available to patients for hematologic diseases, including cancer vaccines, chimeric antigen receptor T cells, and immunotherapies to regulate inflammation in nonmalignant blood disorders.
© 2018 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29728405      PMCID： PMC6032896          DOI： 10.1182/blood-2018-04-840793

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  14 in total

1.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

2.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Authors:  Syed Abbas Ali; Victoria Shi; Irina Maric; Michael Wang; David F Stroncek; Jeremy J Rose; Jennifer N Brudno; Maryalice Stetler-Stevenson; Steven A Feldman; Brenna G Hansen; Vicki S Fellowes; Frances T Hakim; Ronald E Gress; James N Kochenderfer
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

3.  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Authors:  Maksim Mamonkin; Rayne H Rouce; Haruko Tashiro; Malcolm K Brenner
Journal:  Blood       Date:  2015-06-08       Impact factor: 22.113

4.  Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Authors:  Chun-Meng Wang; Zhi-Qiang Wu; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Xiao-Hui Wang; Xiang Li; Ya-Jing Zhang; Wen-Ying Zhang; Mei-Xia Chen; Yan Zhang; Kai-Chao Feng; Yang Liu; Su-Xia Li; Qing-Ming Yang; Wei-Dong Han
Journal:  Clin Cancer Res       Date:  2016-08-31       Impact factor: 12.531

5.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

6.  Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Authors:  Agne Taraseviciute; Victor Tkachev; Rafael Ponce; Cameron J Turtle; Jessica M Snyder; H Denny Liggitt; David Myerson; Luis Gonzalez-Cuyar; Audrey Baldessari; Chris English; Alison Yu; Hengqi Zheng; Scott N Furlan; Daniel J Hunt; Virginia Hoglund; Olivia Finney; Hannah Brakke; Bruce R Blazar; Carolina Berger; Stanley R Riddell; Rebecca Gardner; Leslie S Kean; Michael C Jensen
Journal:  Cancer Discov       Date:  2018-03-21       Impact factor: 39.397

7.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Authors:  James N Kochenderfer; Zhiya Yu; Dorina Frasheri; Nicholas P Restifo; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

8.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Eric Y Chen; Brent L Wood; Harvey A Greisman; Xiaojun Qian; Scott E James; Andrew Raubitschek; Stephen J Forman; Ajay K Gopal; John M Pagel; Catherine G Lindgren; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2008-05-28       Impact factor: 22.113

9.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

10.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Authors:  Saar Gill; Sarah K Tasian; Marco Ruella; Olga Shestova; Yong Li; David L Porter; Martin Carroll; Gwenn Danet-Desnoyers; John Scholler; Stephan A Grupp; Carl H June; Michael Kalos
Journal:  Blood       Date:  2014-03-04       Impact factor: 22.113
View more
  6 in total

1.  The ASH Agenda for Hematology Research: a roadmap for advancing scientific discovery and cures for hematologic diseases.

Authors:  Charles G Mullighan
Journal:  Blood Adv       Date:  2018-10-09

2.  An overview of multiplexed analyses of CAR T-cell therapies: insights and potential.

Authors:  Brittany Paige DePriest; Noah Vieira; Alan Bidgoli; Sophie Paczesny
Journal:  Expert Rev Proteomics       Date:  2021-10-17       Impact factor: 4.250

Review 3.  CRISPR to fix bad blood: a new tool in basic and clinical hematology.

Authors:  Elisa González-Romero; Cristina Martínez-Valiente; Cristian García-Ruiz; Rafael P Vázquez-Manrique; José Cervera; Alejandra Sanjuan-Pla
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 4.  Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications.

Authors:  Maheswaran Solayappan; Adam Azlan; Kang Zi Khor; Mot Yee Yik; Matiullah Khan; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Front Genet       Date:  2022-01-28       Impact factor: 4.599

5.  Aging and immunotherapies: New horizons for the golden ages.

Authors:  Jamie A G Hamilton; Curtis J Henry
Journal:  Aging Cancer       Date:  2020-09-30

6.  Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.

Authors:  Zuyu Liang; Hao Zhang; Mi Shao; Qu Cui; Zhao Wu; Lei Xiao; He Huang; Yongxian Hu
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.